| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 12/11/2001 | US6329373 Metalloproteinase inhibitors |
| 12/11/2001 | US6329365 Inhibitors of interleukin-1β converting enzyme |
| 12/11/2001 | US6329362 Modulation cell adhesion the compounds are able to inhibit the binding of alpha 4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders. |
| 12/11/2001 | US6329358 Pharmaceutical composition suitable for stimulating the multiplication and growth of osteoblasts |
| 12/11/2001 | US6329354 Administering bone active phosphonate, administering estrogen hormone |
| 12/11/2001 | US6329159 An antibody or antigen binding fragment which binds mammalian chemokine receptor and inhibits the binding of ligand to the receptor; therapy and diagnosis of inflammatory disease associated with mucosal tissues |
| 12/11/2001 | US6328997 Magnesium bicarbonate |
| 12/11/2001 | CA2329482C Recombinant antibodies specific for tnf-.alpha. |
| 12/11/2001 | CA2300703C Method for treating excessive sweating |
| 12/11/2001 | CA2300464C Method for treating headache |
| 12/11/2001 | CA2117953C Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| 12/08/2001 | CA2349776A1 Novel crystalline forms of (3s-trans)-2-¬3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2h-1-benzopyran-7-yl|-4-(trifluoromethyl)-benzoic acid |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |
| 12/06/2001 | WO2001092491A2 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | WO2001092340A2 Use of interleukin-4 antagonists and compositions thereof |
| 12/06/2001 | WO2001092332A1 Feline hepatocyte growth factor |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092256A1 2,7-naphthyridine derivatives |
| 12/06/2001 | WO2001092253A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 12/06/2001 | WO2001092230A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 12/06/2001 | WO2001092227A1 Chemical compounds |
| 12/06/2001 | WO2001092224A1 Indole derivatives with vascular damaging activity |
| 12/06/2001 | WO2001092221A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 12/06/2001 | WO2001092220A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 12/06/2001 | WO2001092218A2 Polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | WO2001092202A1 Il-8 receptor antagonists |
| 12/06/2001 | WO2001091793A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 12/06/2001 | WO2001091787A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | WO2001091744A1 Methods of treating androgen deficiency in men using selective antiestrogens |
| 12/06/2001 | WO2001091734A2 Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases |
| 12/06/2001 | WO2001091729A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 12/06/2001 | WO2001091682A1 Composition and applicator for topical substance delivery |
| 12/06/2001 | WO2001049673A3 Compounds and methods for modulation of estrogen receptors |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001034646A3 Recombinant gelatins |
| 12/06/2001 | WO2001034201A3 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 12/06/2001 | WO2001034181A3 Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene |
| 12/06/2001 | WO2001021605A8 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food |
| 12/06/2001 | WO2001019800A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 12/06/2001 | WO2001018042A3 Apoptosis proteins |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001010847A8 Novel integrin receptor antagonists |
| 12/06/2001 | WO2000061750A3 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 12/06/2001 | US20010049449 Aromatic sulfonyl alpha-cycloamino hydroxamates and their use as MMP inhibitors |
| 12/06/2001 | US20010049371 Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | US20010048929 Novel multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| 12/06/2001 | DE10026699A1 Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage Formulation of heparin, glycosaminoglycan or Heparinoidbasis and use of the formulation and the formulation base |
| 12/06/2001 | CA2736344A1 Tnf-.alpha. production inhibitors |
| 12/06/2001 | CA2617253A1 Synergistic agents for enhancing tissue repair |
| 12/06/2001 | CA2411323A1 Il-8 receptor antagonists |
| 12/06/2001 | CA2410935A1 Novel polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | CA2410903A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | CA2410762A1 Feline hepatocyte growth factor |
| 12/06/2001 | CA2410087A1 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | CA2410084A1 Transporters and ion channels |
| 12/06/2001 | CA2409617A1 2,7-naphthyridine derivatives |
| 12/06/2001 | CA2409311A1 Regulators of apoptosis |
| 12/06/2001 | CA2409267A1 Use of interleukin-4 antagonists and compositions thereof |
| 12/06/2001 | CA2406979A1 Indole derivatives with vascular damaging activity |
| 12/05/2001 | EP1160255A1 Monovalent antibody fragments |
| 12/05/2001 | EP1160254A1 Human vanilloid receptor-like proteins |
| 12/05/2001 | EP1159960A1 Pharmaceutical compositions based on diclofenac |
| 12/05/2001 | EP1159457A1 T cell receptor vbeta beta-jbeta) sequence and methods for its detection |
| 12/05/2001 | EP1159438A1 Means and methods for fibroblast-like or macrophage-like cell transduction |
| 12/05/2001 | EP1159418A2 Muc-1 antagonists and methods of treating immune disorders |
| 12/05/2001 | EP1159417A2 Polynucleotides and proteins encoded thereby |
| 12/05/2001 | EP1159412A2 Composition, methods and reagents for the synthesis of a soluble form of human phex |
| 12/05/2001 | EP1159404A2 Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| 12/05/2001 | EP1159300A2 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 12/05/2001 | EP1159292A2 Compounds having growth hormone releasing activity |
| 12/05/2001 | EP1159291A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 12/05/2001 | EP1159286A1 Tumor necrosis factor receptors 6 alpha and 6 beta |
| 12/05/2001 | EP1159284A1 33 human secreted proteins |
| 12/05/2001 | EP1159268A1 N-SUBSTITUTED BENzOYL INDOLES AS ESTROGENIC AGENTS |
| 12/05/2001 | EP1159265A1 C-16 unsaturated fp-selective prostaglandins analogs |
| 12/05/2001 | EP1159262A1 Tyrosine alkoxyguanidines as integrin inhibitors |
| 12/05/2001 | EP1158996A1 Novel amide derivatives as growth hormone secretagogues |
| 12/05/2001 | EP1158988A2 Corticosteroid formulation |
| 12/05/2001 | EP1158986A1 Protease inhibitors |
| 12/05/2001 | EP1158958A1 Improved powdery pharmaceutical compositions for inhalation |
| 12/05/2001 | EP1017377B1 Use of 6, 7-substituted 2-aminotetralines for the treatment of cytokine mediated inflammatory conditions |
| 12/05/2001 | EP0937036B1 Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors |
| 12/05/2001 | CN1325534A Apparatus and method for brachytherapy |
| 12/05/2001 | CN1325408A Compounds with growth hormone releasing propenties |
| 12/05/2001 | CN1325390A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 12/05/2001 | CN1325389A 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 12/05/2001 | CN1325384A Anthranilic acid amides and the use thereof as medicaments |
| 12/05/2001 | CN1325376A Novel compounds and medicinal use thereof |
| 12/05/2001 | CN1325310A Remedies for bone metabolic errors |
| 12/05/2001 | CN1325303A Tocopherols, tocotrienols, other chroman and side chain derivatives and uses |
| 12/05/2001 | CN1325302A Use of dialkylfumarates |
| 12/05/2001 | CN1325299A Orally administered controlled drug delivery system providing temporal and spatial control |
| 12/05/2001 | CN1324951A High-efficiency expression and application of human recombinant interferon B |
| 12/05/2001 | CN1324651A Bone wound treating medicine |
| 12/05/2001 | CN1324650A Effective medicine for treating cervical vertebra disease as one kind of intractable disease |
| 12/05/2001 | CN1324633A Hyperosteogeny-treating capsule |
| 12/05/2001 | CN1324626A Mongolia medicine for treating pain of cervical vertebra, lumber vertebra and joints |
| 12/05/2001 | CN1324623A Rheumatism treating medicine powder |
| 12/05/2001 | CN1324622A Bone-strengthening and pus-drawing out ointment |